| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11940-017-0468-Z |
| P698 | PubMed publication ID | 28741120 |
| P50 | author | Caterina Mariotti | Q67211429 |
| Franco Taroni | Q67510435 | ||
| P2093 | author name string | Anna Bersano | |
| Gloria Bedini | |||
| Eugenio Agostino Parati | |||
| Silvia Baratta | |||
| Joshua Oskam | |||
| P2860 | cites work | CADASIL in central Italy: a retrospective clinical and genetic study in 229 patients | Q60469194 |
| Angiographic complications in CADASIL | Q73164640 | ||
| The phenotypic spectrum of CADASIL: clinical findings in 102 cases | Q77568574 | ||
| The natural history of CADASIL: a pooled analysis of previously published cases | Q77835119 | ||
| Diagnostic strategies in CADASIL | Q78415468 | ||
| Motor cortex cholinergic dysfunction in CADASIL: a transcranial magnetic demonstration | Q80160482 | ||
| Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies | Q80357378 | ||
| Co-aggregate formation of CADASIL-mutant NOTCH3: a single-particle analysis | Q84235340 | ||
| Memantine for dementia | Q22252980 | ||
| Homocysteine-lowering interventions for preventing cardiovascular events | Q24186605 | ||
| Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery | Q24202939 | ||
| Memantine for dementia | Q24246560 | ||
| The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients | Q24629786 | ||
| Notch signaling: cell fate control and signal integration in development | Q27861061 | ||
| Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients | Q28255796 | ||
| Ergotamine in the acute treatment of migraine: a review and European consensus | Q28378061 | ||
| Notch signaling | Q29618190 | ||
| Notch3 is a major regulator of vascular tone in cerebral and tail resistance arteries | Q30486605 | ||
| Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease | Q30492865 | ||
| Cerebral hemorrhages in CADASIL: report of four cases and a brief review | Q30620885 | ||
| Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals | Q30833390 | ||
| CADASIL and CARASIL. | Q30861866 | ||
| Role of electron microscopy in the diagnosis of cadasil syndrome: a study of 32 patients | Q31120190 | ||
| Case report: bipolar disorder as the first manifestation of CADASIL | Q31165840 | ||
| The spectrum of Notch3 mutations in 28 Italian CADASIL families | Q33214090 | ||
| Cadasil | Q33470786 | ||
| Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/JK signaling Pathway | Q33909665 | ||
| Plasma homocysteine as a risk factor for dementia and Alzheimer's disease | Q33957399 | ||
| Cerebral microbleeds in CADASIL. | Q34092506 | ||
| Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis | Q34106491 | ||
| Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy | Q34295928 | ||
| Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL. | Q34631936 | ||
| Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials | Q34647375 | ||
| Pericytes are involved in the pathogenesis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy | Q35757111 | ||
| Recent progress on small vessel disease with cognitive impairment | Q35870878 | ||
| Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, genetic homogeneity, and mapping of the locus within a 2-cM interval | Q35882443 | ||
| Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience | Q35973490 | ||
| Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects | Q36288849 | ||
| The NOTCH3 score: a pre-clinical CADASIL biomarker in a novel human genomic NOTCH3 transgenic mouse model with early progressive vascular NOTCH3 accumulation | Q36417190 | ||
| CADASIL mutations and shRNA silencing of NOTCH3 affect actin organization in cultured vascular smooth muscle cells | Q36459076 | ||
| Genetics of ischaemic stroke | Q36713912 | ||
| Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL | Q36904906 | ||
| The comparisons of phenotype and genotype between CADASIL and CADASIL-like patients and population-specific evaluation of CADASIL scale in China | Q36922449 | ||
| Investigation of the NOTCH3 and TNFSF7 genes on C19p13 as candidates for migraine | Q36961494 | ||
| Psychiatric disturbances in CADASIL: a brief review | Q37126773 | ||
| Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients | Q37158175 | ||
| Notch and vascular smooth muscle cell phenotype. | Q37342396 | ||
| Considerations on a mutation in the NOTCH3 gene sparing a cysteine residue: a rare polymorphism rather than a CADASIL variant | Q37388350 | ||
| CADASIL management or what to do when there is little one can do. | Q37390715 | ||
| Spontaneous intracerebral hemorrhage in CADASIL | Q37426546 | ||
| Therapeutic strategies in migraine patients with mood and anxiety disorders: clinical evidence | Q37750571 | ||
| Pathogenesis of CADASIL: transgenic and knock-out mice to probe function and dysfunction of the mutated gene, Notch3, in the cerebrovasculature | Q37802293 | ||
| Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression. | Q37894535 | ||
| Rapid improvement of a complex migrainous episode with sodium valproate in a patient with CADASIL. | Q37953847 | ||
| Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis | Q38183266 | ||
| Homocysteine and migraine. A narrative review | Q38194756 | ||
| Therapeutic modulation of Notch signalling--are we there yet? | Q38208211 | ||
| Interpretation of NOTCH3 mutations in the diagnosis of CADASIL. | Q38213076 | ||
| Effects of sapropterin on endothelium-dependent vasodilation in patients with CADASIL: a randomized controlled trial | Q38424269 | ||
| Successful Use of Intravenous Tissue Plasminogen Activator as Treatment for a Patient with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy: A Case Report and Review of Literature. | Q38726318 | ||
| CADASIL: Imaging Characteristics and Clinical Correlation | Q38945618 | ||
| Results of a multicenter, double-blind, randomized, parallel-group, placebo-controlled, single-dose study comparing the fixed combination of acetaminophen, acetylsalicylic acid, and caffeine with ibuprofen for acute treatment of patients with severe | Q39208535 | ||
| Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept. | Q39970746 | ||
| Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. | Q40120849 | ||
| Predictors of Clinical Worsening in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy: Prospective Cohort Study | Q40310544 | ||
| Brain volume changes in CADASIL: a serial MRI study in pure subcortical ischemic vascular disease | Q40323159 | ||
| Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: a two-year follow-up study | Q40375032 | ||
| Notch3 is required for arterial identity and maturation of vascular smooth muscle cells | Q40408474 | ||
| Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients | Q40483321 | ||
| A two-year clinical follow-up study in 80 CADASIL subjects: progression patterns and implications for clinical trials | Q40508931 | ||
| Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison. | Q40729011 | ||
| Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia | Q41611079 | ||
| Reduced cerebrovascular CO(2) reactivity in CADASIL: A transcranial Doppler sonography study | Q42497899 | ||
| Cholinergic neuronal deficits in CADASIL. | Q42504530 | ||
| Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: from stroke to vessel wall physiology | Q43071273 | ||
| Acetazolamide improves cerebral hemodynamics in CADASIL. | Q43130867 | ||
| Comparison of clinical, familial, and MRI features of CADASIL and NOTCH3-negative patients | Q43206146 | ||
| Recommendations for the predictive genetic test in Huntington's disease | Q43453202 | ||
| Hyperhomocysteinemia in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). | Q43836523 | ||
| Cerebral hemodynamics and white matter hyperintensities in CADASIL. | Q44456707 | ||
| Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals | Q44523405 | ||
| Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction | Q44649021 | ||
| Positron emission tomography examination of cerebral blood flow and glucose metabolism in young CADASIL patients | Q44797133 | ||
| Parkinsonism is a late, not rare, feature of CADASIL: a study on Italian patients carrying the R1006C mutation | Q44872355 | ||
| The influence of genetic and cardiovascular risk factors on the CADASIL phenotype | Q44960188 | ||
| Homocysteine and stroke: evidence on a causal link from mendelian randomisation | Q45225758 | ||
| Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine. | Q45975872 | ||
| Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: A meta-analysis | Q46344721 | ||
| Galantamine therapy in dementia associated with CADASIL | Q46358259 | ||
| Does donepezil improve executive function in patients with CADASIL? | Q46736693 | ||
| Characterization of Notch3-deficient mice: normal embryonic development and absence of genetic interactions with a Notch1 mutation | Q47408089 | ||
| CADASIL mimicking multiple sclerosis: The importance of clinical and MRI red flags. | Q47970947 | ||
| Hereditary multi-infarct dementia. Morphological and clinical studies of a new disease | Q48271434 | ||
| Cysteine-sparing CADASIL mutations in NOTCH3 show proaggregatory properties in vitro | Q48368188 | ||
| Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study | Q48470173 | ||
| Systemic blood pressure profile in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy | Q48699356 | ||
| Clinical Pregenetic Screening for Stroke Monogenic Diseases: Results From Lombardia GENS Registry | Q48704656 | ||
| Cognition in CADASIL. | Q48810511 | ||
| MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. | Q48955726 | ||
| Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking | Q49057398 | ||
| CADASIL presenting as schizophreniform organic psychosis. | Q51038579 | ||
| Low blood pressure and the risk of dementia in very old individuals. | Q51944569 | ||
| Intracerebral hemorrhages in CADASIL. | Q53583841 | ||
| Blood pressure and dementia in persons 75+ years old: 3-year follow-up results from the Kungsholmen Project. | Q53758300 | ||
| Notch3 ectodomain is a major component of granular osmiophilic material (GOM) in CADASIL | Q57187397 | ||
| Impaired vasoreactivity in mildly disabled CADASIL patients | Q60445604 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 31 | |
| P577 | publication date | 2017-09-01 | |
| P1433 | published in | Current treatment options in neurology | Q26842298 |
| P1476 | title | CADASIL: Treatment and Management Options | |
| P478 | volume | 19 |
Search more.